N-Zyme BiomedicalBiotech
N-Zyme Biomedical develops enzyme-based biomedical solutions for therapeutic applications.
$4.6MSeries A
Investor undisclosed
A $4.6M Series A for an enzyme-therapy company signals biotech investors are still backing platform plays with narrow initial indications—this isn't a hot category moment, but rather patient capital betting on technical moats. They're likely funding manufacturing scale-up and IND-enabling studies, which means 18-24 months to clinical data. If you're in synthetic biology or protein engineering, watch whether N-Zyme's go-to-market strategy (licensing vs. direct development) becomes the template for other enzyme platforms.